Drug updated on 3/28/2024
| Dosage Form | Injection (intravenous; 20 mg/mL) |
| Drug Class | Neonatal Fc receptor blockers |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
Summary
- Efgartigimod alfa-fcab (Vyvgart) is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
- A total of one systematic review/meta-analysis document was reviewed, providing insights into Vyvgart's efficacy and comparison with other treatments.
- The study assessed the effectiveness of Vyvgart after 28 days of treatment, along with several other drugs including eculizumab, ravulizumab, rozanolixizumab, zilucoplan and rituximab over varying periods.
- In terms of overall mean Myasthenia Gravis-Activities of Daily Living scale score change compared to placebo (-2.17 points), no significant difference emerged between complement inhibitors and anti-FcRn treatments like Vyvgart.
- However, when considering changes in Quantitative Myasthenia Gravis scale scores (-3.46), FcRn treatments such as Vyvgart showed a higher reduction than others (-4.78 vs -2.60).
- In a network meta-analysis within this study's limitations including efficacy time points considered; it was found that among all tested therapies for MG patients, Vyvagrt had the highest probability being most effective followed by Rozanolixizumab while Rituximab did not show any significant benefit for these patients.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Vyvgart (efgartigimod alfa-fcab) Prescribing Information. | 2022 | argenx BV, Zwijnaarde, Belgium |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis. | 2023 | European Journal of Neurology |
| Assessment report: Vyvgart. | 2022 | EMA |
| Eculizumab and efgartigimod for the treatment of myasthenia gravis: effectiveness and value. | 2021 | ICER |